Sun Talks Up Remedial Measures At Troubled Plant After Report
This article was originally published in PharmAsia News
Executive Summary
Indian drug maker Sun Pharma is irked by a news report that cited documents from the U.S. FDA and highlighted a practice of deletion of test data at its Karkhadi-based manufacturing site. The same site was served a Warning Letter earlier this year.